A novel combined chemotherapy using TS-1 and low-dose cisplatin against liver metastasis of gastric cancer

Yoshiro Saikawa, Toshio Kanai, Yukio Kawano, Yoshihide Otani, Tetsuro Kubota, Masaki Kitajima

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

We used a novel combination chemotherapy of TS-1 and low-dose cisplatin (CDDP) with 4 gastric cancer patients with liver metastases (one far advanced and 3 recurrent patients). TS-1 was administered at 80 mg-120 mg/body/day, twice daily for 3 weeks followed by a 2-week interval as one cycle, and CDDP was administered at 6 mg/m2/day div, for 5 days followed by a 2-day interval (1 cycle for an inpatient) or at 6 mg/m2/day div, at 5 times for 2-3 weeks (1 cycle for an outpatient). Efficacy and toxicity were evaluated after 3-6 cycles of the regimen, as long as the patients tolerated the regimen without severe side effects. This regimen resulted in 1 complete response, 2 partial responses and 1 progressive disease, showing a 75% efficacy rate. One patient experienced grade 2 nausea from this regimen, which was ameliorated by means of prolonging the interval of CDDP-administration. Thus, the regimen is useful to maintain patients' quality of life without severe adverse effects, and has a high efficacy in gastric cancer patients with liver metastases.

Original languageEnglish
Pages (from-to)1241-1245
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume29
Issue number7
Publication statusPublished - 2002 Jul

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A novel combined chemotherapy using TS-1 and low-dose cisplatin against liver metastasis of gastric cancer'. Together they form a unique fingerprint.

Cite this